SWSarah Tennant Withers

Sarah Tennant Withers

*This is an algorithmically generated author record based on publicly available information.

Sarah Tennant Withers has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time to antibiotic administration in intra-amniotic infections: impact of cefoxitin monotherapy versus traditional antibiotic therapy

    by Hannah Bischoff, Sarah Tennant Withers, Caroline Jozefczyk, Joseph Kohn, R. Jake Crocker, Jasmine Lewis, Carolyn Ellison, Joseph A. Ewing, Pamela Bailey

    Objective: This study addresses treatment of intra-amniotic infection (IAI) by comparing timely receipt of recommended antibiotic administration between cefoxitin and traditional antimicrobial therapy, ampicillin and gentamicin, with or without clindamycin. Methods: This retrospective cohort study was conducted at a large, multi-site health system. The combination therapy group treated with ampicillin plus gentamicin, with or without clindamycin from June 2022 to May 2023, was compared to patients treated with cefoxitin from June 2023 to May 2024, following an institutional guideline update. Participants: Pregnant individuals aged 16 and older with diagnosed or presumed IAI were included. Results: Three hundred patients were included, 150 each in both the combination therapy and cefoxitin groups. Baseline characteristics were similar between the combination therapy and cefoxitin patients. Vaginal delivery was the most common mode of delivery, and rates of cesarean delivery were similar between groups. Most patients had a negative group B Streptococcus screen. Timely receipt of antimicrobials within 60–90 minutes of order entry occurred in significantly more patients in the cefoxitin group compared to combination therapy group (69.3% vs 4.7%, P < .001). Time to recommended therapy was significantly shorter in the cefoxitin group (76.4 ± 93.3 vs 183.7 ± 228.9 min, P < .001). There were no differences in mortality, 30-day infection-related readmission, or need for additional surgical/procedural intervention. Conclusions: Cefoxitin for IAI significantly improves timeliness of recommended antibiotic treatment, aligning with current guideline recommendations for prompt therapy. The absence of differences in secondary outcomes supports the clinical efficacy of cefoxitin and its consideration as a first-line agent in the management of IAI.

  • Inpatient Antibiotic Stewardship Interventions in the Adult Oncology and Hematopoietic Stem Cell Transplant Population: A Review of the Literature

    by Kelly E. Pillinger, Jeannette Bouchard, Sarah T. Withers, Krutika Mediwala, Edoabasi U. McGee, Geneen M. Gibson, Christopher M. Bland, P. Brandon Bookstaver

    Objective: To review the use of antibiotic stewardship interventions in the adult oncology and hematopoietic cell transplantation (HCT) populations. Data Sources: A literature search of PubMed was performed from inception to October 31, 2019. The general search terms used were oncology, cancer, hematologic malignancy, antimicrobial stewardship, antibiotic stewardship, febrile neutropenia, neutropenic fever, de-escalation, discontinuation, prophylaxis, practice guidelines, clinical pathway, rapid diagnostics, Filmarray, Verigene, MALDI-TOF, antibiotic allergy, and antimicrobial resistance. Study Selection and Data Extraction: Relevant English-language studies describing interventions supported by the Infectious Diseases Society of America guidelines on “Implementing an Antibiotic Stewardship Program” were included. Data Synthesis: Antibiotic stewardship publications in the oncology population have increased in recent years. Studies have described the impact of stewardship interventions, including preauthorization, prospective audit and feedback, implementation of clinical pathways, de-escalation of empirical antibiotics for febrile neutropenia (FN) prior to neutrophil recovery, allergy assessments, and use of rapid diagnostic testing. Many of these interventions have been shown to decrease antibiotic use without increased negative consequences, such as affecting length of stay or mortality. Relevance to Patient Care and Clinical Practice: This review synthesizes available evidence for implementing antibiotic stewardship interventions, particularly de-escalation of antibiotics for FN and implementation of clinical pathways for FN and sepsis, in oncology patients and HCT recipients. Summary tables highlight studies and specific research needs for clinicians. Conclusions: Immunocompromised populations, including oncology patients, have often been excluded from stewardship studies. Antibiotic stewardship is effective in reducing antibiotic consumption and improving outcomes in this patient population, although more quality data are needed.